2015 Annual SIOPEL Spring Meeting


The next SIOPEL group spring meeting will take place in Oslo, Norway, 24-25 April 2015. Attached you will find the details and the booking forms to register.





SIOPEL guidelines for the treatment of hepatoblastoma


SIOPEL recommends the treatment strategy for Hepatoblastoma patients not entered into a clinical trial:

Standard Risk Tumours: 4 cycles of CISPLATIN preoperative chemotherapy followed by surgical resection and 2 post operative cycles of therapy.

High risk tumours: the preoperative dose intensive “superPLADO” arm of the SIOPEL 3 study (Zsiros et al 2010 J Clin Oncol 28:2584). We would also recommend consultation at the time of diagnosis with a specialist liver surgery/transplant service.

Very high risk tumours: These tumours are defined by the presence of metastatic disease (usually lung) or very low AFP (<100 ng/ml). They should be treated with the approach utilised in the SIOPEL4 protocol with dose-intensive weekly cisplatin/doxorubicin induction therapy. This is an experimental regimen with limited pilot data shortly to be published.

One will find details LINK



Childhood Liver Tumours Strategy Group - SIOPEL

The ultimate goal of the SIOPEL study group is to improve the prognosis and the quality of life of children affected by primary childhood liver tumors.

Primary hepatic tumours represent less than 1% of all childhood malignancies. Their frequency according to the different series is of about 0.8 - 1 case per million children less than 15 years of age per year. Hepatoblastoma (HB) is by far the commonest histological subtype of primary malignant hepatic tumours occurring in children less than 15 years of age, followed by hepatocellular carcinoma (HCC).

SIOPEL Group is composed of basic and clinical scientists coming from different European and Extra-European countries.